Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Phase 4

Completed

• Conditions: Diabetes
• Interventions: Drug: Gliclazide; Drug: Glibenclamide

• Registration Number: NCT02201602
• Lead Sponsor: Khoo Teck Puat Hospital

Brief Summary

Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.

Detailed Description

Sulphonylurea (SU) is a glucose-lowering agent used widely to treat type 2 diabetes mellitus (T2DM). SU promotes insulin secretion from the pancreatic islet beta cell via binding and inhibition of the ATP-sensitive potassium (KATP) channel. The KATP channel is made up of two subcomponents, an inner Kir6.2 K+ channel (coded by the KCNJ11 gene) and an outer SU receptor 1 (SUR1) (coded by the ABCC8 gene). Although all SUs are mechanistically similar in terms of increasing insulin secretion, they bind to distinct regions of Kir 6.2 and SUR1 to exert their function. Different types of SU (e.g. tolbutamide, glibenclamide, glipizide, glimepiride and gliclazide) can therefore be grouped by their binding sites (A/B/A+B site) on the KATP channel \[3\]. Interestingly, the KCNJ11 E23K (rs5219) variant was shown to confer susceptibility to T2DM and the ABCC8 S1369A (rs757110) variant was found to be in complete linkage disequilibrium with it i.e. inherited together as a genetic block (haplotype). A recent in vitro molecular study suggested that the minor haplotype (K23/A1369) of KATP channel is sensitive to inhibition by gliclazide (binds to A-site) but not glibenclamide (binds to A+B site), and that the increased responsiveness to gliclazide was largely due to the A1369 allele. Understanding how the response to these two SUs may vary with the presence of the minor haplotype (K23/A1369) would therefore be beneficial for customization of patient treatment to achieve better clinical outcomes.

Study Timeline

• Study First Submitted: 2014-07-22
• Study First Submitted QC: 2014-07-25
• Study First Posted: 2014-07-28
• Study Start: 2014-08
• Primary Completion: 2016-06
• Study Completion: 2016-07
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-31
• Last Update Posted: 2016-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

• Type 2 diabetes
• Age 21-65
• HbA1c >8.0% on two consecutive visits

Exclusion Criteria

• Currently taking insulin at a regime more complex than basal insulin
• Not willing to perform self-blood glucose monitoring (SBGM)
• Renal impairment i.e. eGFR<50mls/min
• Pregnancy or unwilling to practice adequate contraception
• Taking other medications that may affect blood glucose e.g. systemic glucocorticoids.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Gliclazide	Gliclazide	Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
Glibenclamide	Glibenclamide	Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks

Primary Outcome Measures

Name	Time	Method
Mean blood glucose level	6 days

Secondary Outcome Measures

Name	Time	Method
Glycemic variability	6 days	Glycemic variability will be assessed using the EasyGV software (http://www.phc.ox.ac.uk/research/diabetes/software/easygv/) which is capable of calculating 10 different measures of glycemic variability from continuous glucose monitoring data, such as Standard Deviation (SD) and M-value, mean amplitude of glycemic excursions (MAGE).

Trial Locations

Locations (1)

Khoo Teck Puat Hospital; 🇸🇬 Singapore, Singapore